Press Releases for KG

Press Releases
King Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
King Pharmaceuticals to Present at Credit Suisse Healthcare Conference
King Pharmaceuticals to Present at UBS Global Life Sciences Conference
Acura Pharmaceuticals and King Pharmaceuticals Provide Update on Acurox® NDA
BenchmarkJournal.Com Free Analyst Review for ANN, GGB, KG, PFG, IAG and QTM
DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain
King Pharmaceuticals Reports Second Quarter 2009 Financial Results
Pain Therapeutics Reviews Mid-Year Progress, Reports Second Quarter 2009 Financial Results
Ligand Pharmaceuticals Announces Second Quarter Results
Acura Pharmaceuticals Reports Second Quarter 2009 Financial Results
King Pharmaceuticals Announces Date for Release of Second Quarter 2009 Earnings
King Provides Additional Information on the REMOXY(R) NDA Resubmission Plan
King and Pain Therapeutics Announce REMOXY(r) NDA Update
REMOXY(R) NDA Update
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Alpharma's Reach Teach Learn Initiative Targets Youth and Consumer Awareness
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
King Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
King Pharmaceuticals Appoints John J. Howarth Vice President Investor Relations
King Pharmaceuticals Reports First-Quarter 2009 Financial Results
King Pharmaceuticals Presents Safety, Efficacy and Measurement Data from Expanded Pain Portfolio
King Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
Excess Oral Doses of Acurox® Tablets are Disliked by Subjects with a History of Opioid Abuse
Acura Pharmaceuticals Reports First Quarter 2009 Financial Results
AnalystChoice.Com Free CFA Opinion on CYH, KG, ILMN and SEIC
Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times
King Pharmaceuticals to Present at Cowen and Company Health Care Conference
Acurox(r) Tablets New Drug Application Accepted for Filing With a Priority Review Classification
King Pharmaceuticals Reports Year-End and Fourth-Quarter 2008 Financial Results
King Pharmaceuticals Plans Webcast to Review Financial Results for the Fourth-Quarter and Year-End 2008 and Provide Strategic Update
King Pharmaceuticals Offers New Dosage Strengths of AVINZA® to Provide More Treatment Options for People with Chronic Pain
King Pharmaceuticals Announces Corporate Restructuring to Reduce Operating Expenses
King Pharmaceuticals Announces Positive Results from a 12-Month Open-Label Safety and Efficacy Study of EMBEDA™ Extended Release Capsules
King Pharmaceuticals to Present at JPMorgan Healthcare Conference
New Drug Application Submitted For Acurox(r) Tablets
King Pharmaceuticals Provides Update on EMBEDA™ NDA Review
King Completes Acquisition of Alpharma
King Pharmaceuticals Initiates Phase II Clinical Trial Evaluating T-62 as a Treatment for Neuropathic Pain
BenchmarkJournal.Com (Complimentary) Analyst Review for BAX, KG, CVX and WHR
U.S. Federal Trade Commission Provisionally Accepts Consent Decree and Terminates Waiting Period for King Pharmaceuticals’ Acquisition of Alpharma
King Pharmaceuticals Exercises Option to License Fourth Opioid Product From Acura Pharmaceuticals
King Extends Tender Offer for Alpharma
King Pharmaceuticals Announces Submission of New Drug Application for CorVue™
Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications
King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
Zacks #1 Rank Top Performers: American Science and Engineering, Allegiant Travel, Alpharma, Hanger Orthopedic and Emergency Medical Services
Seven Summits Research Releases Comments on QCOM, HAL, ERTS, KG, and DF
King Pharmaceuticals Reports Third-Quarter 2008 Financial Results
King Pharmaceuticals Announces Date for Release of Third-Quarter 2008 Financial Results
Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of Key Clinical Study Assessing Abuse Liability
King Pharmaceuticals Extends Tender Offer to Acquire Alpharma
King Pharmaceuticals Responds to Alpharma Inc.
King Commences Cash Tender Offer for Alpharma at $37 Per Share
King to Commence Cash Tender Offer for Alpharma at $37 Per Share
King Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
Pain Therapeutics and King Pharmaceuticals Develop a New Abuse-Resistant Prescription Pain Medication
King Pharmaceuticals Provides Updated Replay Information for Conference Call Regarding Proposed Acquisition of Alpharma
Alpharma Responds to Unsolicited Proposal by King Pharmaceuticals, Inc.
King Proposes Acquisition of Alpharma for $33 Per Share in Cash
Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland
FDA Accepts REMOXY New Drug Application and Grants Priority Review
FDA Accepts REMOXY New Drug Application and Grants Priority Review
King Pharmaceuticals Reports Second-Quarter 2008 Financial Results
King Pharmaceuticals Supports Time To Talk(TM) Education Campaign
King Pharmaceuticals Announces Date for Release of Second-Quarter 2008 Financial Results and Conference Call
King Pharmaceuticals to Present at Leerink Swann Pain Roundtable Conference
Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
King Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
King Pharmaceuticals Reports First-Quarter 2008 Financial Results - Jun 1 2008 11:48PM
King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal Phase III Clinical Trial Evaluating ACUROX(TM)
King Pharmaceuticals Announces Date for Release of First Quarter 2008 Earnings
Seven Summits Research Releases Alerts on PFE, WFR, AES, KG, and PKS